Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease.

ABSTRACT:

Background

Determining the extent of cryptococcal disease (CD) is key to therapeutic management. Treatment with fluconazole is only recommended for localised pulmonary disease. Induction therapy with amphotericin B (AmB) and flucytosine is recommended for disease at other sites, irrespective of central nervous system (CNS) involvement, but this is not often followed in patients without meningitis. In this study, we compared treatment and mortality between patients with CD of the CNS and other extrapulmonary (OE) sites.

Methods

This is a retrospective, single-centre study of all hospitalised patients with nonpulmonary cryptococcal infection from 2002 to 2015 who underwent lumbar puncture. Demographics, predisposing factors, comorbidities, clinical presentation, laboratory val

SUBMITTER: Mejia-Chew C 

PROVIDER: S-EPMC7855417 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature